2014
Predictors of Abstinence from Heavy Drinking During Treatment in COMBINE and External Validation in PREDICT
Gueorguieva R, Wu R, O'Connor PG, Weisner C, Fucito LM, Hoffmann S, Mann K, O'Malley SS. Predictors of Abstinence from Heavy Drinking During Treatment in COMBINE and External Validation in PREDICT. Alcohol Clinical And Experimental Research 2014, 38: 2647-2656. PMID: 25346505, PMCID: PMC4397985, DOI: 10.1111/acer.12541.Peer-Reviewed Original ResearchAcamprosateAge FactorsAlcohol AbstinenceAlcohol DeterrentsAlcohol DrinkingBehavior TherapyCombined Modality TherapyControlled Clinical Trials as TopicDecision TreesGamma-GlutamyltransferaseGermanyGoalsHumansLogistic ModelsMiddle AgedNaltrexonePredictive Value of TestsRandomized Controlled Trials as TopicReproducibility of ResultsTaurineTime FactorsTreatment OutcomeUnited States
2012
Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients
Tetrault JM, Moore BA, Barry DT, O'Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. Journal Of Substance Use And Addiction Treatment 2012, 43: 433-439. PMID: 22938914, DOI: 10.1016/j.jsat.2012.07.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineBuprenorphine, Naloxone Drug CombinationCounselingDelivery of Health Care, IntegratedFeasibility StudiesFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPsychotherapy, BriefSubstance Abuse DetectionTime FactorsTreatment OutcomeViral LoadConceptsEnhanced medical managementPhysician managementDetectable HIV viral loadHIV treatment settingsOpioid-negative urinesBuprenorphine/naloxoneHIV viral loadOpioid-dependent patientsPercentage of subjectsUntreated opioid dependenceExtended counselingHIV clinicHIV outcomesBuprenorphine/Medical managementOpioid dependenceViral loadDependent patientsExtensive counselingClinical trialsContinuous abstinenceNegative urineTreatment settingsGroup differencesCounseling
1999
Plasma concentrations of buprenorphine 24 to 72 hours after dosing
Chawarski MC, Schottenfeld RS, O’Connor P, Pakes J. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug And Alcohol Dependence 1999, 55: 157-163. PMID: 10402160, DOI: 10.1016/s0376-8716(98)00192-6.Peer-Reviewed Original ResearchConceptsDose scheduleWithdrawal symptomsPlasma concentrationsDaily buprenorphine doseHigh-dose scheduleThrice-weekly scheduleAdministration of buprenorphineOpiate-dependent subjectsHigher plasma concentrationsUse of heroinBuprenorphine doseDaily administrationOutpatient clinicPlasma levelsSublingual administrationAgonist effectsOpiate useHeroin useLow doseHigh doseBuprenorphine solutionMg/70High dosesConcentration 24Dependent subjects